Anti-Phosphocholine Antibody Engineering for Stable, High-Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapies, including antibodies, that bind phosphocholine (PC) to target oxidized phospholipids (OxPL) across a wide range of diseases, as excessive amounts of OxPLs contribute to chronic inflammation and the pathogenesis of cardiopulmonary disorders and neurodegenerative processes.
Innovation Solution
Development of antibodies that specifically bind to phosphocholine (PC) with high affinity, stability, and favorable immunogenicity profiles, which can be produced at high yields, and are used in pharmaceutical compositions for treating inflammatory disorders and degenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are developed to bind phosphocholine with high affinity, then therapeutic effectiveness is improved, but manufacturing complexity and production cost increase
Solution Approach 1:
The patent uses phage display technology to create copies of antibody fragments (scFv) that bind to phosphocholine. These copied antibody sequences are then expressed in bacterial systems (E. coli) to produce the therapeutic antibodies, simplifying the manufacturing process while maintaining high affinity binding capability.
Solution Approach 2:
The patent replaces complex traditional antibody production methods with a bacterial expression system. Instead of using mammalian cell cultures or complex purification processes, the invention uses E. coli to express and produce the antibody fragments, significantly simplifying the manufacturing complexity while maintaining therapeutic effectiveness.
2Stability of the object's composition
If antibodies are engineered for high stability and stress resistance, then therapeutic durability is improved, but immunogenicity risk increases
Solution Approach 1:
The patent optimizes the antibody sequences by modifying specific amino acid parameters to enhance stability and reduce immunogenicity. The sequences are engineered to have improved physicochemical properties that increase therapeutic durability while minimizing the risk of immune response in patients.
Solution Approach 2:
The patent uses phage display as an intermediary system to select and optimize antibody sequences. This intermediary platform allows for the selection of sequences that balance stability and immunogenicity by displaying numerous variants and selecting those with optimal properties before final production.
3Productivity
If antibody production yield is increased, then manufacturing efficiency is improved, but purification difficulty increases
Solution Approach 1:
The patent extracts only the essential functional portions of the antibody (scFv fragments) rather than producing full-length antibodies. This extraction approach increases production yield in bacterial systems while simplifying purification, as the smaller fragments can be purified more easily using affinity tags and standard chromatography methods.
Solution Approach 2:
The patent segments the antibody into smaller functional units (scFv fragments) that can be produced independently in bacterial systems. This segmentation allows for higher production yields and easier purification compared to full-length antibodies, as the smaller fragments require less complex purification steps.
Data Source
AI summary
The present disclosure provides polypeptides that specifically bind to phosphocholine (PC). Also provided are pharmaceutical compositions comprising these polypeptides, nucleic acids encoding these polypeptides, expression vectors and host cells for making these polypeptides, and methods of treating a subject using these polypeptides.